Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLC003
MIFTS: 54

Glucose Intolerance

Categories: Metabolic diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Glucose Intolerance

About this section

MalaCards integrated aliases for Glucose Intolerance:

Name: Glucose Intolerance 12 29 54 6 44 15
Impaired Glucose Tolerance 71
Malabsorption of Glucose 12
Glucose: Malabsorption 12
Glucose: Intolerance 12

Classifications:

MalaCards categories:
Global: Metabolic diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:10603
MeSH 44 D018149
NCIt 50 C34646
SNOMED-CT 67 267426009
ICD10 32 R73.03
UMLS 71 C0271650
Sources

Summaries for Glucose Intolerance

About this section
MalaCards based summary : Glucose Intolerance, also known as impaired glucose tolerance, is related to lipodystrophy, familial partial, type 2 and coronary heart disease 1. An important gene associated with Glucose Intolerance is MT-TL1 (Mitochondrially Encoded TRNA-Leu (UUA/G) 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Regulation of lipid metabolism Insulin signaling-generic cascades. The drugs Orlistat and Rosiglitazone have been mentioned in the context of this disorder. Affiliated tissues include ovary, skeletal muscle and endothelial, and related phenotypes are adipose tissue and cardiovascular system

Wikipedia : 74 Prediabetes is a component of the metabolic syndrome and is characterized by elevated blood sugar levels... more...

Sources

Related Diseases for Glucose Intolerance

About this section

Diseases related to Glucose Intolerance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 385)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, familial partial, type 2 32.3 SLC2A4 LEP INS ADIPOQ
2 coronary heart disease 1 31.3 LPL INS ADIPOQ
3 abdominal obesity-metabolic syndrome 1 31.3 SLC2A4 RETN LPL LEPR LEP INSR
4 fatty liver disease 31.2 RETN LEPR LEP INSR INS GPT
5 lipid metabolism disorder 31.1 SHBG RETN LPL LEP INSR INS
6 gestational diabetes 31.1 SLC2A4 SHBG RETN LEPR LEP INSR
7 polycystic ovary syndrome 31.0 SHBG RETN LEP INSR INS IGF1
8 uremia 31.0 RETN LPL LEP INS ENPP1
9 liver disease 31.0 RETN LEPR LEP INSR INS GPT
10 kidney disease 31.0 RETN LEP INS GCG ENPP1 DPP4
11 pre-eclampsia 31.0 LEPR LEP INS IGF1 ADIPOQ
12 atherosclerosis susceptibility 30.9 RETN LPL LEP INS ADIPOQ
13 hypoglycemia 30.9 PCK2 INSR INS IGF1 GCK GCG
14 acute insulin response 30.9 INS GCG
15 hyperglycemia 30.8 RETN PCK2 LPL LEP INSR INS
16 hyperandrogenism 30.8 SHBG INSR INS IGF1 ADIPOQ
17 acromegaly 30.8 SHBG LEPR LEP INS IGF1 GHRL
18 non-alcoholic fatty liver disease 30.7 SLC2A4 RETN LPL LEPR LEP INSR
19 lipoprotein quantitative trait locus 30.7 RETN LPL INS GPT GCG ADIPOQ
20 insulin-like growth factor i 30.7 SHBG LEP INSR INS IGF1
21 hyperthyroidism 30.6 SHBG RETN LEP INS IGF1 GPT
22 genetic obesity 30.6 LEPR LEP IGF1
23 vascular disease 30.6 RETN LPL LEP INS IGF1 ADIPOQ
24 arteriosclerosis 30.6 SHBG INS GPT GHRL ADIPOQ
25 acute pancreatitis 30.6 RETN LPL INS GPT
26 chronic kidney disease 30.6 RETN LPL LEPR LEP INS IGF1
27 fetal macrosomia 30.6 LEP INSR INS IGF1
28 non-alcoholic steatohepatitis 30.6 SLC2A4 LEPR INS IGF1 GPT GHRL
29 hyperinsulinism 30.5 SLC2A4 SHBG RETN LPL LEPR LEP
30 hypothyroidism 30.5 SHBG RETN LEP INS IGF1 GPT
31 sleep apnea 30.5 RETN LEPR LEP INS IGF1 GPT
32 type 1 diabetes mellitus 30.5 RETN LEPR LEP INSR INS IGF1
33 familial hyperlipidemia 30.5 LPL LEP INS GPT ADRB3 ADIPOQ
34 thyroid gland disease 30.4 SHBG LEP INS IGF1 GPT
35 dumping syndrome 30.4 INS GHRL GCG
36 hyperproinsulinemia 30.4 SHBG INS
37 cerebrovascular disease 30.4 RETN LPL LEP INS ADIPOQ
38 diabetes mellitus, ketosis-prone 30.4 INS GCG DPP4
39 acanthosis nigricans 30.4 SLC2A4 SHBG LEP INSR INS IGF1
40 anovulation 30.4 SHBG LEP INS IGF1 GHRL
41 liver cirrhosis 30.3 SLC2A4 RETN LEPR LEP INSR INS
42 body mass index quantitative trait locus 11 30.3 SLC2A4 SHBG RETN LPL LEPR LEP
43 hyperinsulinemic hypoglycemia 30.3 INSR INS GCK GCG
44 hyperprolactinemia 30.3 SHBG INS IGF1
45 eating disorder 30.2 LEPR LEP GHRL GCG ADIPOQ
46 fasting hypoglycemia 30.2 INSR IGF1
47 familial hypercholesterolemia 30.2 LPL INS GPT ADIPOQ
48 permanent neonatal diabetes mellitus 30.2 INS GCK GCG
49 bone resorption disease 30.2 LEP INS IGF1
50 turner syndrome 30.2 SHBG LEP INS IGF1

Graphical network of the top 20 diseases related to Glucose Intolerance:



Diseases related to Glucose Intolerance
Sources

Symptoms & Phenotypes for Glucose Intolerance

About this section

MGI Mouse Phenotypes related to Glucose Intolerance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.32 ADIPOQ ADRB3 ENPP1 GHRL IDE IGF1
2 cardiovascular system MP:0005385 10.23 ADIPOQ DPP4 ENPP1 GCK IDE IGF1
3 homeostasis/metabolism MP:0005376 10.22 ADIPOQ ADRB3 DPP4 ENPP1 GCK GHRL
4 cellular MP:0005384 10.21 ADIPOQ DPP4 ENPP1 GCK IDE IGF1
5 growth/size/body region MP:0005378 10.21 ADIPOQ ADRB3 DPP4 ENPP1 GCK IDE
6 endocrine/exocrine gland MP:0005379 10.18 ADIPOQ ADRB3 DPP4 GCK GHRL IDE
7 immune system MP:0005387 10 ADIPOQ DPP4 ENPP1 IDE IGF1 INS
8 liver/biliary system MP:0005370 9.85 ADIPOQ ENPP1 GCK INS INSR LEP
9 muscle MP:0005369 9.61 ADIPOQ ENPP1 IGF1 INS INSR LEP
10 renal/urinary system MP:0005367 9.23 ADIPOQ ENPP1 GCK IGF1 INS INSR
Sources

Drugs & Therapeutics for Glucose Intolerance

About this section

Drugs for Glucose Intolerance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 392)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
2
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
3
Nitric Oxide Approved Phase 4 10102-43-9 145068
4
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
5
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
6
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
9
Linagliptin Approved Phase 4 668270-12-0 10096344
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
12
Morphine Approved, Investigational Phase 4 57-27-2 5288826
13
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
14
Ethanol Approved Phase 4 64-17-5 702
15
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
16
Losartan Approved Phase 4 114798-26-4 3961
17
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
18
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
19
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
20
Hydroxychloroquine Approved Phase 4 118-42-3 3652
21
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
22
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
23
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
24
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
25
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
26
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
27
Metformin Approved Phase 4 657-24-9 14219 4091
28
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
29
Testosterone Approved, Investigational Phase 4 58-22-0 6013
30
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
31
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
32
Amlodipine Approved Phase 4 88150-42-9 2162
33
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
34
Sodium citrate Approved, Investigational Phase 4 68-04-2
35
Saxagliptin Approved Phase 4 361442-04-8 11243969
36
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
37
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
38
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
39
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
40
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
42
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
43
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
44
Voglibose Investigational Phase 4 83480-29-9 444020
45
Cobalamin Experimental Phase 4 13408-78-1 6857388
46
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
47
Candesartan Experimental Phase 4 139481-59-7 2541
48 Anti-Infective Agents Phase 4
49 Norgestimate, ethinyl estradiol drug combination Phase 4
50 Antifungal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 571)
# Name Status NCT ID Phase Drugs
1 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
2 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
3 Antiatherogenic and Antimetabolic Effect of Curcumin Therapy in the Prevention and Delay of Type 2 Diabetic in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
4 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
5 The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance Unknown status NCT02502344 Phase 4 Metformin
6 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
7 Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome Unknown status NCT03383068 Phase 4 Acarbose 100 MG;Exenatide;Orlistat;Metformin
8 The Effect of Sitagliptin Treatment on Glucose Metabolism and Endothelial Function in Renal Transplant Recipients - JANUVIA-08 Completed NCT00740363 Phase 4 sitagliptin;placebo
9 Effect of Pioglitazone With and Without Exenatide on Body Weight, Fat Topography, Beta Cell Function, and Glycemic Control in Type 2 Diabetic Patients Completed NCT00845182 Phase 4 Pioglitazone;Exenatide;Pioglitazone and Exenatide
10 The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism Completed NCT03398356 Phase 4 Metformin
11 Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women Completed NCT01475513 Phase 4 Ortho Cyclen®
12 Effects of Cyclosporine A on Pancreatic Insulin Secretion Completed NCT00139035 Phase 4 cyclosporine A
13 Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes Completed NCT00212290 Phase 4 pioglitazone;nateglinide;placebo
14 The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study Completed NCT00129233 Phase 4 Valsartan;Amlodipine
15 Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study Completed NCT01964703 Phase 4 Rubus occidentalis extract
16 The Chronic and Acute Postprandial Vascular Effects of Exenatide vs. Metformin in Abdominally Obese Patients With Impaired Glucose Tolerance Completed NCT00546728 Phase 4 Exenatide;Metformin
17 Exercise in Elderly Individuals With Impaired Glucose Tolerance: Beneficial for Vasculature and Neurons? Completed NCT01219231 Phase 4
18 Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes Completed NCT00675740 Phase 4 rosiglitazone
19 Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function Completed NCT01588418 Phase 4 Exenatide;Placebo
20 Postmarketing Clinical Study on AO-128 Completed NCT02287402 Phase 4 AO-128
21 Effect of Dexmedetomidine on Postoperative Glucose Levels and Insulin Secretion Patterns in Obese Patients With Impaired Glucose Tolerance. Completed NCT03809182 Phase 4 Dexmedetomidine;0.9% Sodium-chloride;Fentanyl;Morphine Sulfate
22 Telmisartan vs. Losartan in Hypertensive Patients With Impaired Glucose Tolerance: A Comparison of Their Antihypertensive, Metabolic, and Vascular Effects Completed NCT00407862 Phase 4 Telmisartan 80 mg;Losartan 50 mg
23 A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt) Completed NCT00241072 Phase 4 valsartan
24 Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance Completed NCT00108615 Phase 4 Metformin;Pioglitazone;Metformin;Pioglitazone
25 Efficacy and Safety of Nateglinide Treatment in Renal Treatment Recipients With Post Transplant Diabetes Mellitus or Impaired Glucose Tolerance Completed NCT00319189 Phase 4 Nateglinide
26 Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT) Completed NCT00301392 Phase 4 Life style interventions plus concomitant use of pitavastatin.
27 Blood Pressure and Metabolic Effects of Nebivolol Compared With Hydrochlorothiazide and Placebo in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose Completed NCT00673790 Phase 4 Nebivolol with concomitant losartan or lisinopril;HCTZ with concomitant losartan or lisinopril;Placebo with concomitant losartan or lisinopril
28 Phase IV Study Evaluating the Effect of Sitagliptin (Januviaâ„¢) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes. Completed NCT00627744 Phase 4 Sitagliptin
29 Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS Completed NCT03122041 Phase 4 Sitagliptin
30 A Long-term, Multicentre, Double-blind, Randomised Parallel-group Trial to Determine Whether Reducing Post-prandial Glycaemia Can Reduce Cardiovascular-related Morbidity and Mortality in Patients With Established Coronary Heart Disease or Acute Coronary Syndrome Who Have Impaired Glucose Tolerance Completed NCT00829660 Phase 4 Acarbose;Matching Placebo
31 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
32 Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes Completed NCT02104739 Phase 4 Exenatide;Saxagliptin;Exenatide extended-release (ER)
33 Effects of GH and Pioglitazone in Viscerally Obese Adults With IGT Completed NCT00352287 Phase 4 Recombinant human growth hormone; pioglitazone
34 The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus Completed NCT00456885 Phase 4 exenatide;Placebo
35 The Effect of Metformin on Clinical Course of Ischemic Etiology Chronic Heart Failure in Patients With Prediabetes: the Open-label Randomized Clinical Trial Completed NCT04549415 Phase 4 Metformin Hydrochloride
36 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes Completed NCT02700334 Phase 4 Dapagliflozin;Placebo
37 Mechanisms of Action of Hydroxychloroquine in Reducing Risk of Type 2 Diabetes Completed NCT01326533 Phase 4 hydroxychloroquine
38 Oral Cholecalciferol in Prevention of Type 2 DM in Prediabetic Population With Vitamin D Insufficiency Completed NCT01436916 Phase 4 oral cholecalciferol + life style counselling;placebo + life style counselling
39 Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial Completed NCT01765946 Phase 4 Metformin;placebo
40 Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2 - EVIDENS Completed NCT01497132 Phase 4 Vitamin D3;Placebo
41 Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation Completed NCT00974272 Phase 4 Exenatide
42 Effect of Linagliptin + Metformin on Glucose Metabolism and Pancreatic Beta Cell Function in Patients With Prediabetes Who do Not Achieve Normoglycemia After 12 Months of Treatment With Metformin Alone Completed NCT04088461 Phase 4 Linagliptin / Metformin Oral Tablet;Metformin
43 Diet and Exercise in Type 2 Diabetes and Prediabetes Completed NCT00928005 Phase 4
44 Effect of Dapagliflozin on Blood Pressure Variability in Patients With Prediabetes and Prehypertension Without Pharmacological Treatment Completed NCT03006471 Phase 4 Dapagliflozin;Placebo - Cap
45 Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial Completed NCT03004612 Phase 4 Metformin
46 Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone Completed NCT00746174 Phase 4 Rosiglitazone;Placebo
47 Metformin in Longevity Study (MILES). Completed NCT02432287 Phase 4 Metformin;Placebo
48 The Effect of Korean Red Ginseng Supplementation on Glucose Control in Subjects With Impaired Fasting Glucose, Impaired Glucose Tolerance or Newly-diagnosed Type 2 Diabetes Mellitus Completed NCT01911663 Phase 4
49 Open-label, Flexible-dose Adjunctive Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance Recruiting NCT03575000 Phase 4 Bromocriptine
50 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Recruiting NCT04387201 Phase 4 Dulaglutide;Cyanocobalamin

Search NIH Clinical Center for Glucose Intolerance

Inferred drug relations via UMLS 71 / NDF-RT 51 :


glucomannan

Cochrane evidence based reviews: glucose intolerance

Sources

Genetic Tests for Glucose Intolerance

About this section

Genetic tests related to Glucose Intolerance:

# Genetic test Affiliating Genes
1 Glucose Intolerance 29
Sources

Anatomical Context for Glucose Intolerance

About this section

MalaCards organs/tissues related to Glucose Intolerance:

40
Ovary, Skeletal Muscle, Endothelial, Pancreas, Brain, Adipocyte, Kidney
Sources

Publications for Glucose Intolerance

About this section

Articles related to Glucose Intolerance:

(show top 50) (show all 10374)
# Title Authors PMID Year
1
Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists. 54 61
20469868 2010
2
Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. 61 54
20332348 2010
3
Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans. 54 61
19914667 2010
4
Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. 61 54
20147524 2010
5
Obesity and type 2 diabetes: slow down!--Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage? 61 54
19815054 2010
6
Adiponectin and carotid intimal medial thickness in subjects with and without glucose intolerance (CURES-82). 54 61
20105040 2010
7
Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. 61 54
19804472 2010
8
Adiponectin in insulin resistance: lessons from translational research. 61 54
19906806 2010
9
Retinol-binding protein 4 levels in obese children and adolescents with glucose intolerance. 54 61
20389103 2010
10
Acromegaly pathogenesis and treatment. 61 54
19884662 2009
11
Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses. 61 54
19697961 2009
12
The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. 61 54
19688613 2009
13
The prevalence of abnormal liver enzymes and metabolic syndrome in obese adolescent females with polycystic ovary syndrome. 54 61
19576817 2009
14
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose. 54 61
19542241 2009
15
Cassia cinnamon for the attenuation of glucose intolerance and insulin resistance resulting from sleep loss. 61 54
19627193 2009
16
Pre-gravid physical activity and reduced risk of glucose intolerance in pregnancy: the role of insulin sensitivity. 61 54
18793347 2009
17
Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. 54 61
19003725 2009
18
Early atherosclerosis and vascular inflammation in mice with diet-induced type 2 diabetes. 54 61
19260948 2009
19
Impact of adiponectin and ghrelin on incident glucose intolerance and on weight change. 54 61
18624998 2009
20
Association between insulin resistance, glucose intolerance, and hypertension in pregnancy. 61 54
18847384 2009
21
A cross-sectional study for glucose intolerance of myotonic dystrophy. 54 61
18834994 2009
22
Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. 54 61
18812482 2008
23
Ketogenic diet-fed rats have increased fat mass and phosphoenolpyruvate carboxykinase activity. 61 54
18655006 2008
24
[Polymorphism of glucose intolerance and insulin resistance susceptibility genes in oncological patients]. 61 54
19140314 2008
25
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. 61 54
18854155 2008
26
Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. 54 61
18803955 2008
27
Associations between sex hormone binding globulin and metabolic syndrome parameters in premenopausal obese women. 54 61
19008614 2008
28
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. 54 61
18633104 2008
29
Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. 54 61
18647805 2008
30
High plasma retinol binding protein-4 and low plasma adiponectin concentrations are associated with severity of glucose intolerance in women with previous gestational diabetes mellitus. 54 61
18492757 2008
31
A cross-sectional study of the association between persistent organic pollutants and glucose intolerance among Greenland Inuit. 54 61
18560802 2008
32
Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. 61 54
18334585 2008
33
Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. 61 54
18388893 2008
34
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. 61 54
17706206 2008
35
Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. 61 54
17904401 2008
36
Adiponectin and its role in cardiovascular diseases. 61 54
18336252 2008
37
Insulin and its role in chronic kidney disease. 54 61
17929061 2008
38
Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. 54 61
17944883 2008
39
How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. 61 54
17387006 2007
40
Suppressive effects of diacylglycerol oil on postprandial hyperlipidemia in insulin resistance and glucose intolerance. 54 61
17125771 2007
41
Glucocorticoids and cardiovascular disease. 61 54
17984234 2007
42
Muscle GLUT4 in cirrhosis. 54 61
17448565 2007
43
Fetal determinants of type 2 diabetes. 54 61
17691930 2007
44
Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. 61 54
16814296 2007
45
Early-phase insulin secretion is disturbed in obese subjects with glucose intolerance. 61 54
17512320 2007
46
[Effect of progressive insulin resistance on the correlation of glucose metabolism and bone status]. 54 61
17561482 2007
47
Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. 54 61
17418606 2007
48
Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. 54 61
17403409 2007
49
Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. 54 61
17484056 2007
50
'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies. 54 61
17389771 2007
Sources

Variations for Glucose Intolerance

About this section

ClinVar genetic disease variations for Glucose Intolerance:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-TL1 NC_012920.1:m.3243A>G SNV Pathogenic 9589 rs199474657 MT:3243-3243 MT:3243-3243
Sources

Expression for Glucose Intolerance

About this section
Search GEO for disease gene expression data for Glucose Intolerance.
Sources

Pathways for Glucose Intolerance

About this section

Pathways related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 65
Show member pathways
 13.23 LEPR LEP INSR INS GCG ADRB3
2
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 12.83 SLC2A4 PCK2 INSR INS IGF1 GCK
3
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.68 SLC2A4 RETN LEP INSR INS ADIPOQ
4
Angiopoietin Like Protein 8 Regulatory Pathway 1
Show member pathways
 12.44 SLC2A4 LPL INSR INS ENPP1
5
Glucose / Energy Metabolism 4
12.44 SLC2A4 PCK2 INSR INS GCG ENPP1
6
Prolactin Signaling Pathway 1 36
Show member pathways
 12.39 LEPR LEP INS GCK
7
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.22 SLC2A4 PCK2 LEPR LEP INSR INS
8
Peptide hormone metabolism 65
Show member pathways
 12.17 LEP INS IGF1 GHRL GCG DPP4
9
AMPK Enzyme Complex Pathway 63
Show member pathways
 12.13 SLC2A4 LEP INSR INS
10
Longevity regulating pathway 36
Show member pathways
 12.06 INSR INS IGF1 ADIPOQ
11
FoxO signaling pathway 36
Show member pathways
 12.01 SLC2A4 PCK2 INSR INS IGF1
12
Insulin resistance 36
Show member pathways
 11.88 SLC2A4 PCK2 INSR INS
13
HIF-1 signaling pathway 36
11.86 INSR INS IGF1
14
Glucagon signaling pathway 36
11.85 PCK2 GCK GCG
15
Type II diabetes mellitus 36 1
Show member pathways
 11.84 SLC2A4 INSR INS GCK ADIPOQ
16
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.71 SLC2A4 LPL LEP INS IGF1 ADIPOQ
17
PPAR signaling pathway 36
11.68 PCK2 LPL ADIPOQ
18
Adipocytokine signaling pathway 36
11.6 SLC2A4 PCK2 LEPR LEP ADIPOQ
19
Regulation of lipolysis in adipocytes 36
11.55 INSR INS ADRB3
20
Incretin synthesis, secretion, and inactivation 65
Show member pathways
 11.54 LEP GCG DPP4
21
Development_Leptin signaling via PI3K-dependent pathway 23
11.5 SLC2A4 LEPR LEP
22
Signaling events mediated by PTP1B 1
11.49 LEPR LEP INSR INS
23
Ovarian steroidogenesis 36
11.48 INSR INS IGF1
24
Adipogenesis 1
11.35 SLC2A4 RETN PCK2 LPL LEP INS
25
Aldosterone-regulated sodium reabsorption 36
11.31 INSR INS IGF1
26
Insulin-mediated glucose transport 1
11.19 SLC2A4 INSR INS
27
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.92 LEPR LEP INS GHRL
28
Cori Cycle 1
10.89 SLC2A4 INS GPT
29
Insulin signalling in human adipocytes (diabetic condition) 1
Show member pathways
 10.84 SLC2A4 INSR
30
Transcription factor regulation in adipogenesis 1
10.7 SLC2A4 PCK2 LEP INSR ADIPOQ
Sources

GO Terms for Glucose Intolerance

About this section

Cellular components related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 RETN LPL LEP INS IGF1 IDE
2 cell surface GO:0009986 9.63 SLC2A4 LPL IDE ENPP1 DPP4 ADIPOQ
3 extracellular region GO:0005576 9.44 SHBG RETN LPL LEPR LEP INS

Biological processes related to Glucose Intolerance according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.06 LEP INSR INS IGF1 DPP4
2 positive regulation of protein phosphorylation GO:0001934 9.92 LEPR LEP INSR ADIPOQ
3 carbohydrate metabolic process GO:0005975 9.92 SLC2A4 INSR INS GCK ADRB3
4 insulin receptor signaling pathway GO:0008286 9.84 INSR INS IDE
5 response to nutrient levels GO:0031667 9.83 LEP GHRL ADIPOQ
6 positive regulation of MAPK cascade GO:0043410 9.83 LEP INSR INS IGF1 ADRB3
7 negative regulation of tumor necrosis factor production GO:0032720 9.8 IGF1 GHRL ADIPOQ
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 LEP INSR INS IGF1
9 regulation of insulin secretion GO:0050796 9.78 LEP GCK GCG DPP4
10 positive regulation of cold-induced thermogenesis GO:0120162 9.77 LEPR LEP GHRL ADRB3 ADIPOQ
11 response to activity GO:0014823 9.76 LEP GCG ADIPOQ
12 generation of precursor metabolites and energy GO:0006091 9.74 ENPP1 ADRB3 ADIPOQ
13 positive regulation of insulin secretion GO:0032024 9.73 PCK2 GHRL GCK
14 activation of protein kinase B activity GO:0032148 9.72 INSR INS IGF1
15 glucose metabolic process GO:0006006 9.72 LEP INS GHRL GCK ADIPOQ
16 positive regulation of mitotic nuclear division GO:0045840 9.71 INSR INS IGF1
17 positive regulation of glucose import GO:0046326 9.71 INSR INS IGF1 ADIPOQ
18 positive regulation of glycolytic process GO:0045821 9.69 INSR INS IGF1
19 positive regulation of gluconeogenesis GO:0045722 9.68 GPT GCG
20 negative regulation of glucose import GO:0046325 9.67 LEP ENPP1
21 amyloid-beta clearance GO:0097242 9.67 INSR IDE
22 negative regulation of protein autophosphorylation GO:0031953 9.66 ENPP1 ADIPOQ
23 neuron projection maintenance GO:1990535 9.65 INSR INS
24 cellular response to leptin stimulus GO:0044320 9.65 LEP GCK
25 leptin-mediated signaling pathway GO:0033210 9.64 LEPR LEP
26 sexual reproduction GO:0019953 9.64 LEPR LEP
27 adult feeding behavior GO:0008343 9.63 LEP GHRL
28 energy reserve metabolic process GO:0006112 9.63 LEPR LEP ADRB3
29 negative regulation of feeding behavior GO:2000252 9.62 RETN INS
30 positive regulation of respiratory burst GO:0060267 9.61 INSR INS
31 bone mineralization involved in bone maturation GO:0035630 9.61 LEP IGF1
32 bone growth GO:0098868 9.6 LEPR LEP
33 regulation of bone remodeling GO:0046850 9.59 LEPR LEP
34 positive regulation of developmental growth GO:0048639 9.58 LEP INSR
35 negative regulation of gluconeogenesis GO:0045721 9.56 LEPR INS GCK ADIPOQ
36 glucose homeostasis GO:0042593 9.56 SLC2A4 LEPR LEP INSR INS GCK
37 positive regulation of glycogen biosynthetic process GO:0045725 9.46 INSR INS IGF1 GCK
38 cellular response to insulin stimulus GO:0032869 9.23 SLC2A4 PCK2 LEP INSR GPT GCK

Molecular functions related to Glucose Intolerance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.77 LPL LEP GCG DPP4 ADIPOQ
2 protein homodimerization activity GO:0042803 9.73 LPL IDE ENPP1 DPP4 ADRB3 ADIPOQ
3 insulin receptor binding GO:0005158 9.33 INS IGF1 ENPP1
4 insulin binding GO:0043559 9.32 INSR IDE
5 hormone activity GO:0005179 9.17 RETN LEP INS IGF1 GHRL GCG
6 insulin-like growth factor receptor binding GO:0005159 9.13 INSR INS IGF1
Sources

Sources for Glucose Intolerance

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....